Rutgers Cancer Institute of New Jersey and RWJBarnabas Health Demonstrate Innovation in Oncology Through Extensive Hematology/Oncology Data to Be Presented at the 63rd American Society of Hematology Annual Meeting and Exposition

The institutions' latest advances in hematology/oncology will be showcased through 31 scheduled presentations, including 15 oral presentations

News provided by

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health

Dec 07, 2021, 07:00 ET

NEW BRUNSWICK, N.J., Dec. 7, 2021 /PRNewswire/ -- Physician-scientists from Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility, will present expansive new hematology/oncology data from their clinical research program at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, being held in Atlanta, Georgia (and virtually) from December 11-14, 2021. A total of 31 abstracts have been accepted, with data focusing on the latest surgical and treatment advancements in blood cancers, including pediatric hematology, leukemia, lymphoma and myeloma. Rutgers Cancer Institute, in partnership with RWJBarnabas Health, is New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center.

"Our dynamic teams of nationally renowned cancer specialists and researchers have a deep and ongoing commitment to innovative research in blood cancers, which we proudly look forward to demonstrating through our vast lineup of data at this year's ASH Annual Meeting and Exposition," said Andrew M. Evens, DO, MSc, FACP, Associate Director for Clinical Services, Rutgers Cancer Institute; System Director of Medical Oncology and Oncology Lead for Combined Medical Group, RWJBarnabas Health, who is also an attending physician at Robert Wood Johnson University Hospital. "RWJBarnabas Health, together with Rutgers Cancer Institute of New Jersey, is dedicated to advancing cancer treatments, patient care and ultimately, transforming patient outcomes, with the goal of one day eradicating the disease," adds Dr. Evens, who is also Associate Vice Chancellor, Clinical Innovation and Data Analytics, at Rutgers Biomedical and Health Sciences.

Highlights of the accepted abstracts include the following:

Current NCCN guidelines recommend 1 of 3 first-line regimens for stage III or IV classical Hodgkin lymphoma (cHL). Data from CONNECT, the first real-world observational survey of physicians, patients and caregivers in cHL was designed to understand the decision-making process when selecting a first-line cHL treatment regimen for stage III or IV cHL, and gain insights into physicians' preferred regimens and factors that influence their treatment choices.
Data from a large multicenter real-world evidence analysis of autoimmune (AI) diseases and lymphoma examining the impact of AI diseases on patient outcome across varying lymphoma subtypes, including the role of immunosuppressive medications.
Data from a large retrospective real-world evidence study of newly-diagnosed Primary Central Nervous System Lymphoma (PCNSL) patients. Treatment of older patients with PCNSL is challenging due to the prevalence of comorbidities, frailty and complexities with effective delivery of chemotherapy. This study analyzed post-induction treatment patterns and outcomes across 20 U.S. academic centers.
Research that revealed Sirt1 as a novel therapeutic target in T-cell Acute Lymphoblastic Leukemia (T-ALL). T-ALL is an aggressive hematological malignancy that affects both children and adults, and 20%-50% of patients show primary resistance or relapse after treatment, and ultimately die from their disease.

The full list of presentations at this year's ASH Annual Meeting and Exposition follows:

Oral Presentations
Abstract and Session No.	Title	Presentation Date/Time
Abstract 50 (Session 627)	A Large Multicenter Real-World Evidence (RWE) Analysis of Autoimmune (AI) Diseases and Lymphoma: Histologic Associations, Disease Characteristics, Survival, and Prognostication	Saturday, December 11, 2021, at 9:45 a.m. EST
Abstract 117 (Session 905)	Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple- Class Refractory Multiple Myeloma: Analysis of the Connect® Multiple Myeloma (MM) Disease Registry	Saturday, December 11, 2021, at 10 a.m. EST
Abstract 184 (Session 905)	A Multi-Center Retrospective Review of COVID-19 Outcomes in Patients with Lymphoid Malignancy	Saturday, December 11, 2021, at 12:45 p.m. EST
Abstract 160 (Session 653)	Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in- Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)	Saturday, December 11, 2021, at 12:45 p.m. EST
Abstract 231 (Session 624)	Frontline Treatment with Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy for Classic Hodgkin Lymphoma: Updated Results and Correlative Analysis	Saturday, December 11, 2021, at 2:30 p.m. EST
Abstract 323 (Session 636)	PI3-Kinase Deletion Dysregulates Autophagy in HSCs and Promotes Myelodysplasia	Saturday, December 11, 2021, at 5:00 p.m. EST
Abstract 357 (Session 603)	Pervasive Hypermutation of Super-Enhancer Regions Dysregulates Oncogene Expression in Diffuse Large B-Cell Lymphoma	Sunday, December 12, 2021, at 10:00 a.m. EST
Abstract 455 (Session 627)	High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers	Sunday, December 12, 2021, at 1 p.m. EST
Abstract 532 (Session 627)	Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices	Sunday, December 12, 2021, at 5:15 p.m. EST
Session 605	Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Targeting Mitochondrial Survival Pathways	Monday, December 13, 2021, at 2:45-4:15 p.m. EST
Abstract 814 (Session 623)	Phase II Study of Venetoclax in Combination with Obinutuzumab and Bendamustine in Patients with High Tumor Burden Follicular Lymphoma As Front Line Therapy (PrECOG 0403)	Monday, December 13, 2021, at 5:15 p.m. EST
Abstract 878 (Session 624)	Novel Salvage Regimens Lead to Better Response and Survival in Relapsed Refractory Classic Hodgkin Lymphoma after Autologous Stem Cell Transplant	Monday, December 13, 2021, at 6:30 p.m. EST
Abstract 884 (Session 627)	Outcomes and Treatment Patterns in Patients with Aggressive B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy	Monday, December 13, 2021, at 6:30 p.m. EST
Abstract 879 (Session 624)	Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Large Multi-Trial Analysis Based on Individual Patient Data	Monday, December 13, 2021, at 6:45 p.m. EST
Abstract 917 (Session 901)	Grapes: Trivia Game Increases Sickle Cell Disease Knowledge in Patients and Providers and Mitigates Health Biases	Monday, December 13, 2021, at 7:15 p.m. EST
Poster Presentations
Abstract and Session No.	Title	Presentation Date/Time
Abstract 1460 (Session 627)	Connect® Lymphoma Disease Registry: A US-Based, Prospective, Observational Cohort Study	Saturday, December 11, 2021, at 10 a.m. EST
Abstract 1390 (Session 624)	Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Observations of Physicians on Treatment and Interim PET-Adapted Regimens	Saturday, December 11, 2021, 5:30-7:30 p.m. EST
Abstract 1966 (Session 905)	Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT)—a Cross-Sectional Survey of Patients with Stage III or IV Classical Hodgkin Lymphoma Compared By Age	Saturday, December 11, 2021, 5:30-7:30 p.m. EST
Abstract 1428 (Session 627)	Older Patients with Primary Central Nervous System Lymphoma (PCNSL): Real World Evidence (RWE) of Prognostication and Outcomes with Post-Induction Therapy	Saturday, December 11, 2021, 5:30-7:30 p.m. EST
Abstract 1347 (Session 623)	Production of Anti-Spike Antibodies in Response to COVID Vaccine in Lymphoma Patients	Saturday, December 11, 2021, at 5:30-7:30 p.m. EST
Abstract 1491 (Session 634)	Surpass-ET Trial: A Phase 3, Open-Label, Multicenter, Randomized, Active-Controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 Vs Anagrelide As Second Line Therapy for Essential Thrombocythemia	Saturday, December 11, 2021, at 5:30-7:30 p.m. EST
Abstract 2213 (Session 602)	The Atlas of Blood Cancer Genomes (ABCG) Project: A Comprehensive Molecular Characterization of Leukemias and Lymphomas	Sunday, December 12, 2021, 6-8 p.m. EST
Abstract 2403 (Session 621)	ALK-Negative Anaplastic Large Cell Lymphomas Encompass Distinct Subgroups Including an ALK-Positive-like Subgroup with Favorable Prognosis	Sunday, December 12, 2021, 6-8 p.m. EST
Abstract 2457 (Session 624)	A Multi-Institution Analysis of Relapsed Lymphoma Occurring during Pregnancy Including Pharmacokinetics with Antenatal Checkpoint Inhibitor Therapy	Sunday, December 12, 2021, 6-8 p.m. EST
Abstract 2467 (Session 624)	Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Physician First-Line Treatment Preferences for Stage III or IV Classical Hodgkin Lymphoma	Sunday, December 12, 2021, 6-8 p.m. EST
Abstract 2221 (Session 603)	Sirt1 Is a Novel Therapeutic Target in T-ALL	Sunday, December 12, 2021, 6-8 p.m. EST
Abstract 3853 (Session 704)	Real World Evidence (RWE) of Safety, Efficacy, and Outcomes of CD19 CAR-T Therapy in 20 Patients with Solid Organ Transplant (SOT)-Related Post-Transplant Lymphoproliferative Disorder (PTLD)	Monday, December 13, 2021, 6-8 p.m. EST
Abstract 3407 (Session 614)	Maximal Tolerated Dose Determined for Venetoclax in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory Ph-Negative T-Cell or B-Cell Acute Lymphoblastic Leukemia: Results of Phase 1 Portion of ECOG-ACRIN EA9152	Monday, December 13, 2021, 6-8 p.m. EST
Abstract 3396 (Session 614)	Impact of Age, Body Surface Area, and Body Mass Index on Pegaspargase Toxicity and Pharmacokinetics: A Report from the DFCI ALL Consortium	Monday, December 13, 2021, 6-8 p.m. EST
Abstract 3485 (Session 618)	Performance of Next Generation Sequencing for Minimal Residual Disease Detection for Pediatric Patients with Acute Lymphoblastic Leukemia: Results from the Prospective Clinical Trial DFCI 16-001	Monday, December 13, 2021, 6-8 p.m. EST
Abstract 3100 (Session 114)	Real-World Experience of Patients with Sickle Cell Disease Treated with Voxelotor: A Multicenter, Retrospective Study	Monday, December 13, 2021, 6-8 p.m. EST

About Rutgers Cancer Institute of New Jersey
As New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute, together with RWJBarnabas Health, offers the most advanced cancer treatment options, including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex surgical procedures. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy – many of which are not widely available – patients have access to these cutting-edge therapies at Rutgers Cancer Institute of New Jersey in New Brunswick, Rutgers Cancer Institute of New Jersey at University Hospital in Newark, as well as through RWJBarnabas Health facilities. To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 848-932-8013 or visit www.cinj.org/giving.

For journalists – contact:
Krista Didzbalis
Media Relations Assistant
908-812-6114
[email protected]

For patient appointments/inquiries – contact:
844-CANCERNJ (844-226-2376)

SOURCE Rutgers Cancer Institute of New Jersey and RWJBarnabas Health